{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:18:17Z","timestamp":1783448297369,"version":"3.55.0"},"reference-count":27,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":165,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Physical activity interventions could play a critical role in tolerance and outcome during anti-neoplastic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to evaluate the role of physical activity and its maintenance on treatment safety and efficacy in patients with advanced thyroid cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 28 patients with advanced thyroid cancer, treated with kinase inhibitor therapy for a median follow-up of 26 months. Three modified long-form International Physical Activity Questionnaires were administered before treatment, at an intermediate follow-up point and at the last follow-up point. Metabolic equivalents were calculated at each time point. Tumour response was evaluated according to RECIST, version 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients inactive at baseline experienced more treatment interruptions during both the first (85 vs 30%, P = 0.01) and second half of the follow-up period (85 vs 47%, P = 0.08) and had more frequently a progressive disease (42 vs 14%, P = 0.15), compared to those who were mildly or highly active. Patients who declined their physical activity during treatment had more treatment interruptions (100 vs 31%, P = 0.006), more adverse events considering both the number (&amp;gt;5) and the grade (\u22653) (100 vs 31%, P = 0.006 and 100 vs 38%, P = 0.01), more hospitalization due to toxicities (66 vs 8%, P = 0.008) and a more progressive disease (40 vs 8%, P = 0.09). The number of toxicities was inversely correlated with metabolic equivalents lost (r = \u22120.15, P = 0.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study showing that maintaining adequate physical activity levels is associated with better treatment tolerance and outcomes in advanced thyroid cancer patients on kinase inhibitor therapy, supporting the need for prospective prehabilitation trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-25-0095","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:44:22Z","timestamp":1771235062000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Physical activity and systemic treatment outcomes in advanced thyroid cancer"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-481X","authenticated-orcid":true,"given":"Carla","family":"Colombo","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Ceruti","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Cervellini","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Succi","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"De Leo","sequence":"additional","affiliation":[{"name":"1"},{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Trevisan","sequence":"additional","affiliation":[{"name":"3"},{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Moneta","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Lugaresi","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianlorenzo","family":"Dionigi","sequence":"additional","affiliation":[{"name":"2"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Gazzano","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Persani","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026070713571568800_bib1","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713571568800_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000336977","article-title":"2012 European thyroid association guidelines for metastatic medullary thyroid cancer","volume":"1","author":"Schlumberger","year":"2012","journal-title":"Eur Thyroid J"},{"key":"2026070713571568800_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"key":"2026070713571568800_bib4","volume-title":"EMEA\/H\/C\/00592 \u2013 Human Medicine European Public Assessment Report (EPAR): Sorafenib Accord 2022","author":"European Medicines Agency","year":"2022"},{"key":"2026070713571568800_bib5","volume-title":"EMEA\/H\/C\/003727 \u2013 IG\/1641 \u2013 Human Medicine European Public Assessment Report (EPAR): Lenima 2023","author":"European Medicines Agency","year":"2023"},{"key":"2026070713571568800_bib6","volume-title":"EMEA\/H\/C\/002640 \u2013 II\/0053 \u2013 Human Medicine European Public Assessment Report (EPAR): Cometriq 2023","author":"European Medicines Agency","year":"2023"},{"key":"2026070713571568800_bib7","volume-title":"EMEA\/H\/C\/002315 \u2013 IAIN\/0060G \u2013 Human Medicine European Public Assessment Report (EPAR): Caprelsa 2023","author":"European Medicines Agency","year":"2023"},{"key":"2026070713571568800_bib8","volume-title":"EMEA\/H\/C\/005375 \u2013 PSUSA\/00010917\/202211 \u2013 Human Medicine European Public Assessment Report (EPAR): Retsevmo 2023","author":"European Medicines Agency","year":"2023"},{"key":"2026070713571568800_bib9","volume-title":"EMEA\/H\/C\/004919 \u2013 II\/0030 \u2013 Human Medicine European Public Assessment Report (EPAR): Vitrakvi 2023","author":"European Medicines Agency","year":"2023"},{"key":"2026070713571568800_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070713571568800_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070713571568800_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026070713571568800_bib13","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"29","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070713571568800_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070713571568800_bib15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduction Target Ther"},{"key":"2026070713571568800_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000504048","article-title":"Body composition and leptin\/ghrelin levels during lenvatinib for thyroid cancer","volume":"1","author":"De Leo","year":"2020","journal-title":"Eur Thyroid J"},{"key":"2026070713571568800_bib17","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.3390\/cancers14194569","article-title":"Effect of pre-existent sarcopenia on oncological outcome of advanced thyroid cancer patients treated with tyrosine kinase inhibitors","volume":"19","author":"Dalmiglio","year":"2022","journal-title":"Cancers"},{"key":"2026070713571568800_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66633-6","article-title":"Multimodal prehabilitation and postoperative outcomes in upper abdominal surgery: systematic review and meta-analysis","volume":"14","author":"Amirkhosravi","year":"2024","journal-title":"Sci Rep"},{"key":"2026070713571568800_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijcard.2017.07.037","article-title":"Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: a proof-of-concept RCT","volume":"245","author":"Kirkham","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026070713571568800_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30723","article-title":"Current landscape and support for practical initiation of oncological prehabilitation translatable to thyroid cancer: a position paper","volume":"10","author":"Jack","year":"2024","journal-title":"Heliyon"},{"key":"2026070713571568800_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human participants","volume":"333","author":"World Medical Association","year":"2025","journal-title":"J Am Med Assoc"},{"key":"2026070713571568800_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026070713571568800_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00005768-200009001-00009","article-title":"Compendium of physical activities: an update of activity codes and MET intensities","volume":"32","author":"Ainsworth","year":"2000","journal-title":"Med Sci Sports Exerc"},{"key":"2026070713571568800_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12874-018-0642-3","article-title":"Validity of the International Physical Activity Questionnaire (IPAQ) for assessing moderate-to-vigorous physical activity and sedentary behaviour of older adults in the United Kingdom","volume":"1","author":"Cleland","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2026070713571568800_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00421-012-2421-x","article-title":"Associations between Borg\u2019s rating of perceived exertion and physiological measures of exercise intensity","volume":"113","author":"Scherr","year":"2013","journal-title":"Eur J Appl Physiol"},{"key":"2026070713571568800_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40164-022-00275-0","article-title":"Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model","volume":"11","author":"Liu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"2026070713571568800_bib27","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s11912-022-01304-1","article-title":"Cancer prehabilitation in practice: the current evidence","volume":"24","author":"Coderre","year":"2022","journal-title":"Curr Oncol Rep"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/6\/1\/EO-25-0095.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/6\/1\/EO-25-0095.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0095\/505436\/eo-25-0095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0095\/505436\/eo-25-0095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:58:10Z","timestamp":1783447090000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e250095\/75468\/Physical-activity-and-systemic-treatment-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-25-0095","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e250095"}}